{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T17:23:46Z","timestamp":1774632226639,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grifols SSNA","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13561-019-0237-7","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T14:02:48Z","timestamp":1562335368000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain"],"prefix":"10.1186","volume":"9","author":[{"given":"M. Chris","family":"Runken","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Caraceni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Zipprich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashad","family":"Carlton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bunke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,5]]},"reference":[{"key":"237_CR1","volume-title":"Cirrhosis","author":"National Institute of Diabetes and Digestive and Kidney Diseases, U.S.","year":"2014","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases, U.S. Department of Health and Human Services. In: Cirrhosis; 2014. \n                    https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/cirrhosis\n                    \n                  . Accessed 6 March 2018."},{"key":"237_CR2","unstructured":"European Association for the Study of the Liver. The burden of liver disease in Europe: a review of available epidemiological data. 2013. \n                    http:\/\/www.easl.eu\/medias\/EASLimg\/Discover\/EU\/54ae845caec619f_file.pdf\n                    \n                  . Accessed 8 March 2018."},{"key":"237_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","volume":"44","author":"G D'Amico","year":"2006","unstructured":"D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217\u201331.","journal-title":"J Hepatol"},{"key":"237_CR4","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.jhep.2015.07.004","volume":"63","author":"M Bernardi","year":"2015","unstructured":"Bernardi M, Moreau R, Angeli P, et al. Mechanisms of decompensation and organ failure in cirrhosis: from the peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63:1272\u201384.","journal-title":"J Hepatol"},{"key":"237_CR5","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0016-5085(96)70068-9","volume":"111","author":"A Gines","year":"1996","unstructured":"Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996;111:1002\u201310.","journal-title":"Gastroenterology."},{"key":"237_CR6","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/hep.24786","volume":"55","author":"M Bernardi","year":"2012","unstructured":"Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55:1172\u201381.","journal-title":"Hepatology."},{"key":"237_CR7","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJM199908053410603","volume":"341","author":"P Sort","year":"1999","unstructured":"Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403\u20139.","journal-title":"N Engl J Med."},{"key":"237_CR8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/hep.27709","volume":"62","author":"M Cavallin","year":"2015","unstructured":"Cavallin M, Kamath PS, Merli M, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: a randomized trial. Hepatology. 2015;62:567\u201374.","journal-title":"Hepatology."},{"issue":"5","key":"237_CR9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.jhep.2018.08.009","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Nov;69(5):1207.","journal-title":"J Hepatol"},{"issue":"Suppl 6","key":"237_CR10","first-page":"vi1","volume":"55","author":"KP Moore","year":"2006","unstructured":"Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55(Suppl 6):vi1\u201312.","journal-title":"Gut."},{"key":"237_CR11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/hep.21588","volume":"45","author":"JB Nousbaum","year":"2007","unstructured":"Nousbaum JB, Cadranel JF, Nahon P, et al. Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology. 2007;45:1275\u201381.","journal-title":"Hepatology."},{"key":"237_CR12","first-page":"164","volume":"23","author":"V Arroyo","year":"1996","unstructured":"Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Int Ascites Club Hepatol. 1996;23:164\u201376.","journal-title":"Int Ascites Club Hepatol"},{"key":"237_CR13","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMra0809139","volume":"361","author":"P Gin\u00e8s","year":"2009","unstructured":"Gin\u00e8s P, Schrier RW. Renal failure in cirrhosis. N Engl J Med. 2009;361:1279\u201390.","journal-title":"N Engl J Med"},{"key":"237_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","volume":"105","author":"A Gines","year":"1993","unstructured":"Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology. 1993;105:229\u201336.","journal-title":"Gastroenterology."},{"key":"237_CR15","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/hep.27789","volume":"62","author":"JS Bajaj","year":"2015","unstructured":"Bajaj JS, O\u2019Leary JG, Wong F, et al. Variations in albumin use in patients with cirrhosis: an AASLD members survey. Hepatology. 2015;62:1923\u20134.","journal-title":"Hepatology."},{"issue":"6","key":"237_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/17474124.2018.1460203","volume":"12","author":"P Caraceni","year":"2018","unstructured":"Caraceni P, Pavesi M, Baldassarre M, et al. The use of human albumin in patients with cirrhosis: a European survey. Expert Rev Gastroenterol Hepatol. 2018 Jun;12(6):625\u201332.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"237_CR17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/MCG.0000000000000735","volume":"51","author":"A Garioud","year":"2017","unstructured":"Garioud A, Cadranel J-F, Pauwels A, et al. Albumin use in patients with cirrhosis in France: results of the ALBU-LIVER survey: a case for better EASL guidelines diffusion and\/or revision. J Clin Gastroenterol. 2017;51:831\u20138.","journal-title":"J Clin Gastroenterol"},{"key":"237_CR18","first-page":"8","volume":"14","author":"P Caraceni","year":"2016","unstructured":"Caraceni P, Angeli P, Prati D, Bernardi M. AISF-SIMTI position paper: the appropriate use of albumin in patients with liver cirrhosis. Blood Transfus. 2016;14:8\u201322.","journal-title":"Blood Transfus"},{"key":"237_CR19","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJM199109193251201","volume":"325","author":"P Gin\u00e8s","year":"1991","unstructured":"Gin\u00e8s P, Arroyo V, Vargas V, et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med. 1991;325:829\u201335.","journal-title":"N Engl J Med."},{"key":"237_CR20","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1053\/jhep.2003.50169","volume":"37","author":"J Sola-Vera","year":"2003","unstructured":"Sola-Vera J, Minana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology. 2003;37:1147\u201353.","journal-title":"Hepatology."},{"key":"237_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1023\/B:DDAS.0000020502.46886.c1","volume":"49","author":"CD Wells","year":"2004","unstructured":"Wells CD, Murrill WB, Arguedas MR. Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analyses in chronic liver disease. Digest Dis Sci. 2004;49:453\u20138.","journal-title":"Digest Dis Sci"},{"key":"237_CR22","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1053\/jhep.2002.35819","volume":"36","author":"R Ortega","year":"2002","unstructured":"Ortega R, Gines P, Uriz J, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology. 2002;36:941\u20138.","journal-title":"Hepatology."},{"key":"237_CR23","first-page":"30","volume":"64","author":"O Goyal","year":"2016","unstructured":"Goyal O, Sidhu SS, Sehgal N, Puri S. Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1: a prospective, randomized trial. J Assoc Phys India. 2016;64:30\u20135.","journal-title":"J Assoc Phys India"},{"key":"237_CR24","unstructured":"Lauer Fisher. Lauretax. \n                    https:\/\/www.lauer-fischer.de\/LF\/Seiten\/Verwaltung\/Kundencenter\/1.aspx\n                    \n                  . Accessed 2 February 2018."},{"key":"237_CR25","unstructured":"Agenzia Italiana del Farmaco. \n                    http:\/\/www.aifa.gov.it\/en\n                    \n                  . Accessed 15 November 2017."},{"key":"237_CR26","unstructured":"Nomenclatur of Medicines with financing from Social Secuty in Spain. \n                    https:\/\/www.nomenclator.org\n                    \n                  . Accessed 23 February 2018."},{"key":"237_CR27","unstructured":"INEK G-Drug DRG Report Browser 2018."},{"key":"237_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40620-016-0291-8","volume":"30","author":"A Roggeri","year":"2016","unstructured":"Roggeri A, Roggeri DP, Zocchetti C, Bersani M, Conte F. Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis. J Nephrol. 2016;30:263\u20139.","journal-title":"J Nephrol"},{"key":"237_CR29","unstructured":"BOC Numero 248. Boletin Oficial de Cantabria. Accessed December 2017."},{"key":"237_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/HMER.S87594","volume":"7","author":"D Roggeri","year":"2015","unstructured":"Roggeri D, Roggeri A, Rossi E, et al. Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs. Hepatic Med Evidence Res. 2015;7:37\u201342.","journal-title":"Hepatic Med Evidence Res"},{"key":"237_CR31","unstructured":"DRG Browser 2016. \n                    http:\/\/www.g-drg.de\/\n                    \n                  . Accessed July, 2016."},{"key":"237_CR32","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1185\/03007995.2013.836079","volume":"29","author":"J Marco","year":"2013","unstructured":"Marco J, Barba R, Matia P, et al. Low prevalence of hyponatremia codification in departments of internal medicine and its prognostic implications. Curr Med Res Opin. 2013;29:1757\u201362.","journal-title":"Curr Med Res Opin"},{"key":"237_CR33","unstructured":"Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murica. \n                    http:\/\/www.ffis.es\/investigacion\/precios_pruebas.php\n                    \n                  . Accessed July 10, 2016."},{"key":"237_CR34","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/0016-5085(88)90691-9","volume":"94","author":"P Gines","year":"1988","unstructured":"Gines P, Tito L, Arroyo V, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology. 1988;94:1493\u2013502.","journal-title":"Gastroenterology."},{"key":"237_CR35","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness- the curious resilence of the the $50,000-per-QALY threshold. N Engl J Med. 2014;371:796\u20137.","journal-title":"N Engl J Med"},{"key":"237_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/11586640-000000000-00000","volume":"9","author":"A Gandjour","year":"2011","unstructured":"Gandjour A. Germany's decision rule for seting ceiling priceso f drugs: a comparative analysis with other decision rules. Appl Health Econ Health Policy. 2011;9:65\u201371.","journal-title":"Appl Health Econ Health Policy"},{"issue":"Suppl 1","key":"237_CR37","doi-asserted-by":"publisher","first-page":"P353","DOI":"10.1186\/cc14433","volume":"19","author":"A Farrugia","year":"2015","unstructured":"Farrugia A, Bansal M, Caraceni P. Use of albumin in spontaneous bacterial peritonitis is cost-effective. Crit Care. 2015;19(Suppl 1):P353.","journal-title":"Crit Care"}],"updated-by":[{"DOI":"10.1186\/s13561-020-00265-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T00:00:00Z","timestamp":1587081600000}}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-019-0237-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13561-019-0237-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-019-0237-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T23:07:35Z","timestamp":1593817655000},"score":1,"resource":{"primary":{"URL":"https:\/\/healtheconomicsreview.biomedcentral.com\/articles\/10.1186\/s13561-019-0237-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,5]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["237"],"URL":"https:\/\/doi.org\/10.1186\/s13561-019-0237-7","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s13561-020-00265-0","asserted-by":"object"}]},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,5]]},"assertion":[{"value":"30 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following publication of the original article [1], the authors reported that one of the numbers within Fig.\ufffd\ufffd6 contains a mistake.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following potential competing interests: This study was funded by Grifols SSNA. Author Runken is an employee of Grifols SSNA. Author Bunke was an employee of Grifols at the time of the study. Author Carlton is an employee of Xcenda, LLC, a consultancy that received funding from Grifols to assist in this study. Author Caraceni is an employee of Alma Mater Studiorum University of Bologna, Italy, and has served on an advisory board and received speaker fees from Grifols. Author Fernandez is an employee of University of Barcelona and has received grant and research support along with speaker fees from Grifols. Author Zipprich is an employee of Martin-Luther-University Halle-Wittenberg and has no potential conflicts of interest to report.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}